MEDNAX Inc (NYSE:MD) was the recipient of unusually large options trading on Tuesday. Stock traders bought 818 put options on the company. This represents an increase of approximately 1,335% compared to the typical daily volume of 57 put options.

A number of equities analysts recently commented on the company. Jefferies Group set a $50.00 price objective on MEDNAX and gave the stock a “hold” rating in a report on Tuesday, February 6th. Mizuho set a $53.00 price objective on MEDNAX and gave the stock a “hold” rating in a report on Friday. Stephens set a $62.00 price objective on MEDNAX and gave the stock a “buy” rating in a report on Thursday. Citigroup dropped their price objective on MEDNAX from $52.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. Finally, Robert W. Baird increased their price objective on MEDNAX from $48.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company. MEDNAX currently has an average rating of “Hold” and an average target price of $55.08.

MEDNAX (MD) opened at $53.94 on Friday. MEDNAX has a twelve month low of $40.56 and a twelve month high of $72.13. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $4,922.52, a P/E ratio of 15.63, a price-to-earnings-growth ratio of 1.45 and a beta of 0.31.

MEDNAX (NYSE:MD) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.83 by $0.04. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. The company had revenue of $910.82 million for the quarter, compared to the consensus estimate of $884.55 million. During the same quarter last year, the company posted $1.00 earnings per share. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. equities research analysts forecast that MEDNAX will post 3.62 EPS for the current year.

In related news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total value of $154,740.00. Following the transaction, the insider now owns 35,569 shares in the company, valued at $1,834,649.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.40% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Fuller & Thaler Asset Management Inc. acquired a new position in MEDNAX during the third quarter valued at approximately $103,000. Denali Advisors LLC bought a new stake in shares of MEDNAX in the third quarter valued at approximately $185,000. Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of MEDNAX by 45.3% in the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,230 shares of the company’s stock valued at $226,000 after acquiring an additional 1,630 shares during the period. Delta Capital Management LLC bought a new stake in shares of MEDNAX in the fourth quarter valued at approximately $227,000. Finally, QS Investors LLC boosted its position in shares of MEDNAX by 0.3% in the second quarter. QS Investors LLC now owns 3,812 shares of the company’s stock valued at $230,000 after acquiring an additional 12 shares during the period. Institutional investors own 98.67% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.watchlistnews.com/traders-purchase-large-volume-of-put-options-on-mednax-md/1858419.html.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.